ANZCTR search results

The shortage of donors in heart transplantation remains a global issue. Recently, there has been significant advancement in the field of organ preservation including our recent study using hypothermic oxygenated perfusion (HOPE) in donation after brain death (DBD) donor hearts and clinical experience in heart transplantation using donation after cardiac death (DCD) donor hearts. We hypothesize that combining these methods will provide comparable outcomes to current techniques whilst increasing the number of heart donors to address the shortage of donor organs.

HeartPath+ is a digital educational resource for individuals who have experienced a coronary heart event. The early stages of transition from leaving hospital to coming home is a crucial time where many have felt uncertain and lacked information and support to manage their heart health and transition through to outpatient programs such as cardiac rehabilitation. HeartPath+ has been designed with lived experienced consumers. The aim is to empower and assist Australian living with heart disease and their family to actively manage their heart health.

This project is designed to assess the feasibility and acceptability of using Continuous Glucose Monitor Sensors (CGMS) in people with diabetes attending the Tweed Valley Hospital High Risk Foot Clinic Diabetes Multidisciplinary Team (TVH HRFC Diabetes MDT). The clinic comprises of the lead podiatrist, a diabetes educator and diabetes dietitian as well as consulting medical specialists including vascular, infectious disease, orthopeadic and endocrinology. The MDT clinic manages people with diabetes and active diabetes related foot ulcers, understanding the importance of achieving adequate glucose control to assist in the management of these wounds. The study protocol proposes a randomised feasibility trial where the intervention in the study is the use of CGMS within a cohort in the TVH HRFC Diabetes MDT and comparing this to another group that does not receive the CGMS. Both groups will otherwise receive the usual care that is provided within this clinic. We hypothesize that the use of the CGMS will assist to improve glucose control, improve diet quality, reduce diabetes distress and ultimately improve wound healing. Further, we believe that participants using the sensor will find the process acceptable and beneficial to their care.

Dental pain is a common condition that affects 1 in 5 Australians. Access to timely dental care is often difficulty, leading to many patients seeking care from the Emergency Department, where treatment options are often limited. This study aims to evaluate the use of a single dose of dexamethasone taken as a capsule to reduce pain in patients presenting to the Emergency Department with dental pain. Dexamethasone is a cheap and readily available medication that has few side effects and an excellent safety profile.

Traumatic brain injury (TBI) remains the leading cause of death after injury. In animal models, early treatment with plasma significantly attenuated neurological impairment after TBI. Early treatment with plasma is therefore a potential therapy for moderate to severe TBI that requires assessment in randomised trials. The aim of this study is to undertake a pilot RCT of early plasma versus standard care among patients with moderate to severe TBI.

Police officers experience unrelenting stress on the job, contributing to high rates of psychological distress. This study will examine if an online mental wellbeing program—Mindarma—can increase psychological resilience in Victoria Police officers and reduce psychological distress. If successful, the Mindarma program may be offered to all Victorian police officers as a vital wellbeing tool.

The Angel Catheter© is a temporary filter device that can be inserted at the patient’s bedside by a trained trauma clinician, without needing an IR suite or a specialist radiology team. It combines a clot-catching filter with a standard intravenous catheter through which fluids and medication can be administered, serving dual purposes during the highest PE risk window. The catheter is removed after several days, once blood thinners can safely be administered or a longer-term filter is placed in the IR suite. The device is already approved for use overseas (FDA-approved in the US and CE-certified in Europe) and demonstrated a good safety and efficacy profile in international clinical trials. To date, no Australian trauma centre has evaluated the Angel Catheter. This proof of concept feasibility pilot study will do this for the first time.

This study will compare two commonly used methods of providing pain relief after robotic gynaecological surgery: a TAP block performed by the surgeon during the operation and a TAP block performed by the anaesthetist using ultrasound guidance. Participants will be randomly assigned to receive one of the two techniques. The main aim is to determine whether the surgeon-performed TAP block provides similar pain relief, measured by the amount of opioid pain medication required in the first 24 hours after surgery. We will also compare pain scores, nausea and vomiting, length of hospital stay, complications, and the time taken to perform each technique. The results may help identify the most effective and efficient approach to pain management for patients undergoing robotic gynaecological surgery.

- This study will test the safety of MAR005 in people with Elevated triglyceride levels. - Up to 10 participants will receive two injections of MAR005, - Participants will attend clinic visits for health checks, study assessments, and monitoring. - The study will also assess how the body responds to and processes MAR005 over time.

- This study will test a new investigational medicine called MAR005 in healthy adult volunteers. - The purpose is to find out whether MAR005 is safe and well tolerated when given multiple times. -Researchers will also study how the body absorbs, distributes, and removes the medicine, and how the medicine affects the body. -Participants will be randomly assigned to receive either MAR005 or a MAR001 and neither the participants nor the study team will know which treatment is being given during the study.